Predicting pituitary tumor behavior with markers and scans
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This study looks at whether blood and tissue markers, along with imaging features, can predict how aggressive a pituitary neuroendocrine tumor is and how it may affect long-term health. It aims to improve treatment decisions by better understanding these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a pituitary neuroendocrine tumor (previously called a pituitary adenoma).
- Your diagnosis is based on imaging and, if needed, hormone level tests.
- You have not had radiation, chemotherapy, immunotherapy, or targeted therapy before.
- You do not have known genetic syndromes that cause hormone excess, like Carney or MEN1.
- You do not have another neuroendocrine tumor elsewhere in the body.
- You are at least one month past any major surgery or three months past pituitary surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at stored tumor tissue from people with pituitary neuroendocrine tumors (Pit-NETs). Researchers want to learn more about the tumor's features and how it relates to long-term outcomes.
This study tests whether a structured education program helps patients scheduled for pituitary tumor surgery feel more prepared and informed. You would receive standardized teaching materials before your operation to improve your understanding and comfort with the procedure.
This study looks at neuroendocrine tumors by collecting tissue (when available) and tracking how the disease behaves over time. It may help researchers better understand these cancers, including rare cases of adrenocortical cancer.
This study tests a new type of PET/MRI scan that uses a special tracer (18F-FET) to better find small pituitary tumors that didn't show up on a standard MRI. The goal is to help guide surgery to remove the tumor.
This trial studies whether specific blood “biomarkers” can help confirm a type of cancer called NEN (neuroendocrine neoplasm) and show whether treatment is working early. It may help doctors start or adjust treatment sooner, especially for cancers that are advanced or have spread.
This study uses a special PET scan (18F-FET) to get clearer images of pituitary adenomas (non-cancerous growths at the base of the brain). It is for people who have already had one type of PET scan and can help doctors understand the tumor better without invasive procedures.
Hear when a new Pituitary Adenoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.